LONGEVA.

Thymosin alpha-1: adverse events and evidence limits

In ETASS, intensive-care patients with severe sepsis received subcutaneous thymosin alpha-1 for seven days alongside standard care. Authors reported no attributed serious drug-related events or intolerance withdrawals. [1]

This does not mean no adverse events. Sedation, analgesia and illness limited subjective-symptom assessment; frequencies and another preparation’s safety remain unestablished. [1]

What the studies reported

EffectModel or participantsHow often or as describedSource
Attributed serious drug-related events or intolerance withdrawalsIntensive-care patients with severe sepsis, subcutaneous thymosin alpha-1 for seven days alongside standard care (ETASS)None reported by the authors; this does not mean no adverse events — sedation, analgesia and illness limited subjective-symptom assessment[1]

References

  1. Jianfeng Wu et al. (2013). The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial https://doi.org/10.1186/cc11932.